EXECUTIVE OFFICER / BioTech Lead Capitalist
MAYU YOSHIKAWA, Ph.D.
After working with large pharmaceutical and medical companies as a consultant at McKinsey & Company, Mayu Yoshikawa joined BNV to work more closely with startup companies and support innovation in Japan. In addition to leading BNV’s life science and biotech investments, Mayu is in charge of BNV’s global expansion and acceleration program as one of its core management members. Mayu’s goal is to transform innovations in academia, especially in Japan, into actual products that improve people’s lives and society. Mayu’s research experience includes characterization of the mechanism of piRNAs, those have been linked to gene silencing of retrotransposons and other genetic elements while undergoing molecular biology training as a graduate student at Kyoto University and the University of Tokyo. Mayu also studied drug-resistant tuberculosis strains in a genotyping project at the KwaZulu-Natal Research Institute for TB and HIV (K-RITH) in South Africa.